P1.04-12 Mass Spectrometry-Based Serum Proteomic Signature as a Potential Biomarker for Survival in NSCLC Patients With Immunotherapy

Journal of Thoracic Oncology - United States
doi 10.1016/j.jtho.2018.08.727
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

A Panel of 13-miRNA Signature as a Potential Biomarker for Predicting Survival in Pancreatic Cancer

Oncotarget
Oncology
2016English

From Biomarker Discovery to Proteomic Validation Using Mass Spectrometry

Acta Ophthalmologica
MedicineOphthalmology
2018English

P2.01-61 Body Mass Index Over Time Is Associated With Overall Survival in Advanced NSCLC Patients Treated With Immunotherapy.

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Identification of a Three miRNA Signature as a Novel Potential Prognostic Biomarker in Patients With Blaader Cancer

Oncotarget
Oncology
2017English

Mass Spectrometry-Based N-Glycoproteomics for Cancer Biomarker Discovery

Clinical Proteomics
2014English

Serum Proteomic Signature of Human Chagasic Patients for the Identification of Novel Potential Protein Biomarkers of Disease

Molecular and Cellular Proteomics
BiochemistryMedicineAnalytical ChemistryMolecular Biology
2012English

Statistical Methods for Quantitative Mass Spectrometry Proteomic Experiments With Labeling

2014English

12-Chemokine Gene Signature Identifies Lymph Node-Like Structures in Melanoma: Potential for Patient Selection for Immunotherapy?

Scientific Reports
Multidisciplinary
2012English

The Proteomic Analysis of Human Neonatal Umbilical Cord Serum by Mass Spectrometry

Acta Pharmacologica Sinica
MedicinePharmacology
2009English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy